Axsome Therapeutics Acquires AZD7325, a Novel GABA-A Receptor Positive Allosteric Modulator for Epilepsy Treatment

Thursday, Nov 6, 2025 7:03 am ET1min read

Axsome Therapeutics has acquired AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator licensed from AstraZeneca, to treat epilepsy. AZD7325 has completed Phase 1 trials and demonstrated anti-convulsant effects in preclinical seizure models. Axsome plans to begin Phase 2 trial-enabling activities in 2026 and has acquired Baergic Bio, Inc. to receive worldwide commercial, development, and manufacturing rights to AZD7325.

Axsome Therapeutics Acquires AZD7325, a Novel GABA-A Receptor Positive Allosteric Modulator for Epilepsy Treatment

Comments



Add a public comment...
No comments

No comments yet